LogicBio Therapeutics (OTCMKTS:LOGC) Hits New 12-Month High – Should You Buy?

LogicBio Therapeutics, Inc. (OTCMKTS:LOGC) reached a new 52-week high during mid-day trading on Monday . The company traded as high as $15.25 and last traded at $15.1850, with a volume of 29037 shares. The stock had previously closed at $14.87.

LogicBio Therapeutics Price Performance

The business has a 50-day simple moving average of $11.59 and a two-hundred day simple moving average of $9.70. The company has a debt-to-equity ratio of 0.29, a quick ratio of 1.24 and a current ratio of 1.87. The company has a market capitalization of $687.78 million, a price-to-earnings ratio of -20.60 and a beta of 2.11.

LogicBio Therapeutics (OTCMKTS:LOGC) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.10). The company had revenue of $33.60 million during the quarter, compared to analysts’ expectations of $33.60 million.

About LogicBio Therapeutics

LogicBio Therapeutics was a clinical-stage genetic medicine company focused on developing treatments for rare and serious genetic diseases. The company’s research centered on technologies designed to modify or deliver genetic material directly inside the body.

LogicBio’s principal technology platforms included GeneRide, an in vivo gene-insertion approach intended to enable long-term expression of therapeutic genes, and GeneWare, a genome-editing platform. Its lead investigational program, LB-001, was developed as a potential treatment for methylmalonic acidemia, a rare inherited metabolic disorder.

Founded in 2014 and headquartered in Cambridge, Massachusetts, LogicBio operated primarily as a biotechnology research and development company serving the rare-disease and genetic-medicine markets.